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Abstract: Thyroid gland presents a wide spectrum of tumours derived from follicular cells that range from well 
differentiated, papillary and follicular carcinoma (PTC and FTC, respectively), usually carrying a good prognosis, to the 
clinically aggressive, poorly differentiated (PDTC) and undifferentiated thyroid carcinoma (UTC). 
It is usually accepted that PDTC and UTC occur either de novo or progress from a pre-existing well differentiated 
carcinoma through a multistep process of genetic and epigenetic changes that lead to clonal expansion and neoplastic 
development. Mutations and epigenetic alterations in PDTC and UTC are far from being totally clarified. Assuming that 
PDTC and UTC may derive from well differentiated thyroid carcinomas (WDTC), it is expected that some PDTC and 
UTC would harbour genetic alterations that are typical of PTC and FTC. This is the case for some molecular markers 
(BRAF and NRAS) that are present in WDTC, PDTC and UTC. Other genes, namely P53, are almost exclusively detected 
in less differentiated and undifferentiated thyroid tumours, supporting a diagnosis of PDTC or, much more often, UTC. 
Thyroid-specific rearrangements RET/PTC and PAX8/PPAR, on the other hand, are rarely found in PDTC and UTC, 
suggesting that these genetic alterations do not predispose cells to dedifferentiation. In the present review we have 
summarized the molecular changes associated with the two most aggressive types of thyroid cancer.  
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INTRODUCTION 
 Undifferentiated thyroid carcinoma (UTC), a term we 
will use as a synonym for anaplastic carcinoma, ranks among 
the most lethal of all human malignancies [1-2] and 
represents nowadays less than 3% of all clinically recognized 
malignant thyroid neoplasms [2]. UTC is more common in 
females and in elderly patients, usually in their seventh 
decade. UTCs are usually non-encapsulated, extensively 
invading the perithyroid tissues. Grossly, the neoplasms have 
fleshy, tan-white appearance, with haemorrhagic and 
necrotic areas, and are composed, at the microscopic level, 
of cells with spindle, polygonal or giant-cell morphology. 
Due to airway obstruction, local invasion, vascular invasion 
and/or distant metastases to lung and bone, and to a striking 
resistance to any type of therapy, the patients usually die 
within a few months after diagnosis [3]. 
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 UTCs may coexist with, or follow, either a well 
differentiated thyroid carcinoma (WDTC) or a long standing 
goiter in about 30% of cases [1, 4]. The anaplastic 
transformation of a WDTC, namely a papillary thyroid 
carcinoma (PTC) or, less often, a follicular thyroid 
carcinoma (FTC) or a poorly differentiated thyroid 
carcinoma (PDTC), is accepted as an intermediate step of 
UTC development [4]. The absence of foci of WDTC close 
to UTC in many cases may be explained by insufficient 
sampling or by overgrowth of the UTC, obscuring a putative 
pre-existing WDTC [1]. Furthermore, there are UTCs which 
are thought to appear de novo. Although some authors have 
reported the presence of calcitonin immunostaining of 
neoplastic cells in some cases of UTC,
 
the existence of a 
UTC made of C-cells is not recognized [2], since the origin 
of UTC from C-cells has never been demonstrated.  
 The diagnostic situation regarding PDTC is much less 
clear than that of UTC. The diagnostic criteria applied to 
PDTC by different groups over the last 25 years have varied 
a lot and the first consensus was only obtained in the 2004 
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WHO classification [2]. PDTC was then recognized as a 
distinct entity, being defined as a thyroglobulin-producing 
non-follicular non-papillary thyroid carcinoma, disclosing 
distinctive high grade features (necrosis and mitoses) and a 
well-developed insular, trabecular or solid pattern of growth 
present in the majority of the tumour, quite often admixed 
altogether within the same tumour and less frequently in a 
“pure” form. This definition places PDTC as a follicular cell-
derived carcinoma with morphological and biological 
attributes intermediate between differentiated and 
undifferentiated thyroid carcinomas [2]. PDTC represents 2-
4% of all thyroid carcinomas and comprises a 
morphologically heterogeneous group of tumours [1, 5-7].  
 PDTC encompasses at least two major types of tumours: 
the so-called insular or insular-like carcinomas and a 
heterogeneous group of carcinomas that also fit into the 
umbrella descriptive designation of PDTC displaying 
predominantly trabecular or solid growth pattern [8]. Using 
immunohistochemistry, lectin histochemistry, electron 
microscopy and molecular genetics, we verified that the 
“pure” insular or insular-like PDTC resemble follicular 
carcinomas (namely widely invasive follicular carcinomas 
with a solid growth pattern), whereas in a proportion of 
PDTC displaying trabecular or solid growth pattern one can 
find features characteristic of PTC [8]. In both instances, foci 
of necrosis and high mitotic rate may be used in individual 
cases as signs suggestive of PDTC, but should not be 
considered as absolute criteria, namely whenever dealing 
with a solid/trabecular variant of PTC, in which the presence 
of necrotic foci and/or numerous mitoses should not lead to a 
diagnosis of PDTC, provided the nuclei are of the PTC-type 
throughout the tumour [7, 9].  
 At present there is a general consensus to diagnose a 
PDTC on the following issues: a) Presence of conventional 
criteria of malignancy and unequivocal signs of follicular 
cell derivation of tumour cells; b) Presence of a solid, 
trabecular, or insular pattern of growth in an otherwise 
malignant thyroid tumour; c) Absence of the conventional 
nuclear features of PTC; d) Presence of convoluted nuclei 
and/or mitotic activity (>3 mitoses/10 HPF) and/or necrosis; 
e) PDTCs composed of oxyphilic, mitochondrion-rich 
Hürthle cells do not constitute a separate entity but rather an 
oncocytic variant of PDTC; and f) The finding of a 
concurrent better differentiated papillary or follicular 
carcinoma component does not preclude the diagnosis of 
PDTC [7, 10]. 
 Genetic alterations in PDTC and UTC are far from being 
totally clarified. The quite different percentages of molecular 
alterations reported in different series of PDTC (e.g. BRAF 
mutations, RET/PTC rearrangement and -catenin 
mutations), probably reflect the discrepancies in the 
classification and the heterogeneity of tumours that are often 
included under the umbrella category of PDTC (namely PTC 
with morphological signs of poor differentiation: solid, 
insular and trabecular foci). Assuming that PDTC and UTC 
may derive from WDTC, it is expected that some PDTC and 
UTC will harbour genetic alterations that are typical of PTC 
and FTC [11]. As we will see, this is the case for some 
molecular markers (BRAF and NRAS) that are present in 
WDTC, PDTC and UTC. Other genes, namely P53, are 
almost exclusively found in PDTC and UTC, indicating a 
UTC or, less often, a PDTC diagnosis. Thyroid specific 
rearrangements namely RET/PTC and PAX8/PPAR, on the 
other hand, are rarely found in PDTC and UTC, suggesting 
that these genetic alterations do not predispose cells to 
dedifferentiation. 
BRAF IN POORLY DIFFERENTIATED AND 
UNDIFFERENTIATED THYROID CARCINOMAS  
 The RAF family encodes serine/threonine kinases that 
are key signal transducers of diverse extracellular stimuli and 
activate mitogen-activated protein kinase (MAPK) signalling 
pathway [12]. The RAF family is composed of three 
different isoforms, ARAF, RAF- 1 (or CRAF) and BRAF 
that, despite the high sequence and structural similarities, are 
differentially regulated. After the identification of BRAF 
mutations in a wide variety of human cancers, namely 
melanoma, ovarian carcinoma and microsatellite unstable 
colorectal carcinomas [13], we and others have reported a 
high prevalence (30% to 69%) of BRAF point mutations in 
PTC [14-18]. These mutations were roughly limited to the 
hotspot identified in melanomas, T1799A leading to V600E 
substitution. Other, less frequent, BRAF mutations were also 
detected in PTC, namely the K601E that we found almost 
exclusively in the follicular variant of PTC [19]. 
 BRAF mutations in PTC seem to be an alternative event 
to RET/PTC rearrangements and to RAS mutations [16, 18]. 
There is also recent evidence showing an association 
between the presence of BRAF mutations and PTC 
recurrence, mortality and resistance to radioiodine therapy 
[20-22], that is probably related to the association of BRAF 
mutations with silencing of iodine-handling genes [23] and 
to the demonstration that BRAF-mutated PTC may evolve to 
PDTC and UTC. 
 In accordance with a stepwise progression model, BRAF 
mutations are more frequent in PDTC arising from PTC,
 
than 
in PDTC associated with FTC [14, 24]. This was clear when 
we evaluated a group of PDTC exclusively composed of 
insular and insular-like tumours, thus excluding PDTC with 
foci displaying PTC nuclei. No BRAF mutations were 
detected in this group, supporting the assumption that pure 
insular and insular-like PDTC are more closely related to 
FTC than to PTC [24]. BRAF mutations were nevertheless 
described in PDTC with PTC-like nuclei, as well as in PDTC 
coexisting with foci of PTC [14, 22]. 
 Treatment of thyroid carcinomas, including PTC, FTC 
and PDTC, is usually achieved through surgical removal and 
the use of radioactive iodine (
131
I). Although the large 
majority of WDTC respond well to radioiodine therapy, 
there are thyroid tumours not responsive to this therapy, 
namely some PTC variants that are inoperable and have lost 
radioactive iodine avidity, as well as some carcinomas 
composed of oncocytic (Hürthle) cells and some less 
differentiated thyroid tumours [22]. The demonstration that 
BRAF mutations are associated with silencing of iodine-
transporting genes in thyroid cancer indicates that targeting 
BRAF may contribute for improving the iodine uptake 
ability of thyroid cancer cells [21, 23, 25].  
 Ricarte-Filho et al. [22] reported recently that PDTC, 
FDG-PET positive tumours refractory to radioactive iodine 
treatment, harbour BRAF mutations in 39% of the samples, 
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whereas non-refractory PDTC display a significantly lower 
frequency of BRAF mutations (12%) [22]. 
 BRAF
 
mutations have also been described in 10% to 
44% of UTC [14, 22, 24]; in such BRAF-mutated UTC, the 
mutations are frequently detected in adjacent foci of PTC 
that are thought to represent the origin of UTC. This 
supports the idea that BRAF mutations can be implicated in 
the progression of WDTC to PDTC or UTC[26-27], at 
variance with what has been described for other genetic 
changes, namely RET/PTC and PAX8/PPAR rearrang-
ements (see below).  
RAS IN POORLY DIFFERENTIATED AND UNDIF-
FERENTIATED THYROID CARCINOMAS  
 RAS genes, namely N-RAS but also H-RAS and K-RAS, 
are consistently found mutated in less differentiated thyroid 
tumours. The prevalence of RAS mutations ranges between 
18 and 55% in PDTC [9] and between 4 and 60% in UTC 
[22, 28-32].  
 The prognostic value of RAS mutations in thyroid cancer 
is not well established. In some series, RAS mutations were 
shown to be associated with aggressive tumour phenotypes 
and poor prognosis [9, 30], whereas in others such an 
association was not observed [22]. It has been advanced that 
cases with mutated N-RAS are significantly associated with 
the appearance of haematogenous (particularly bone) 
metastases, suggesting a role of RAS genes activation in the 
metastatic capability of these tumours [28-29, 33].  
 Due to the association found between RAS mutations and 
guarded prognosis in PDTC and UTC, Wang et al. proposed 
that a particular attention should also be paid to WDTC, 
namely FTC, harbouring RAS mutations [34-35]. 
P53 IN POORLY DIFFERENTIATED AND UNDIF-
FERENTIATED THYROID CARCINOMAS  
 It was hypothesized that UTC may progress from BRAF-
mutated PTC by acquisition of an additional p53 mutation 
[32]. Protein expression and gene mutation analysis of p53 in 
WDTC show that p53 mutation is an extremely rare event in 
these carcinomas; in fact, more than 98% of the WDTC 
(PTC and FCT) analysed have a normal p53 gene [11, 36-
40]. 
 In this respect, thyroid tumours do not follow the 
classical Vogelstein model, in which p53 mutation is a 
crucial step in the first phases of progression (from adenoma 
to carcinoma) [41]. In thyroid tumours, p53 gene inactivation 
seems to play an important role in the progression from 
differentiated to undifferentiated carcinoma, being a late 
event in the carcinogenic process and occurring together 
with a marked increase of cell proliferation [42-45]. The 
analysis of the expression and/or mutations of p53 in PTC 
co-existing with undifferentiated carcinomas, has shown that 
p53 expression/mutation is only found in the undifferentiated 
components [45].  
 P53 mutations have been reported in approximately 26% 
of PDTC and in more than 60% of UTC [11]. Virtually all 
the mutations reported are located in the known hot-spots 
(exons 5-9), being 273 the codon most often affected [37-39, 
46-47].  
 Progression and dedifferentiation in thyroid tumours 
seems to follow a particular pattern. It is possible that the 
progression in vivo results from a two-step mechanism, in 
which there is the need for a differentiation switch, but also 
for a p53 mutation to arise independently in the same cell, 
before any selective advantage is obtained [48-49]. Taking in 
consideration the data on the progression of WDTC (no p53 
mutations) to PDTC and UTC, which frequently harbour p53 
inactivation, gross genetic alterations and aneuploidy, it is 
likely that in the more advanced steps of progression, p53 
inactivation (“suppressor pathway”) represents the most 
frequent mechanism of chromosome instability in thyroid 
cancer. This is in accordance with the sequential increase in 
chromosomal complexity observed in CGH studies from 
WDTC to PDTC and UTC, in terms of the presence and 
number/case of CGH detectable abnormalities [50-53]. 
 The frequency of p53 mutations in UTC reported in the 
different series lies between 60 and 83% [11, 22, 38-39]. 
Even considering the different sensitivities of the different 
methodologies, it is tempting to advance that, at least in a 
minority of cases, alterations in genes other than p53 can 
lead to a similar end stage of thyroid tumour development. 
The prognosis is similar in UTC with and without p53 
mutations, a finding that supports the existence of alternative 
pathways to achieve a similar end result; WNT pathway and 
CDK/CDKI molecules, which were found altered in thyroid 
cancer cell lines and/or primary tumours [54-55] appear to be 
good candidates (see below). We have also evaluated the 
role of p63 that, in its deltaN form, can act as a dominant 
negative of p53, in dedifferentiation/progression from 
WDTC to UTC. Our results do not support the hypothesis 
that p63 overexpression may serve as an alternative 
molecular mechanism to overcome p53 activity in WDTC or 
in UTC [56].  
RET/PTC AND PAX8/PPAR  REARRANGEMENTS 
IN PDTC AND UTC 
 Rearrangements involving the RET oncogene 
(RET/PTC) are commonly found in PTC. RET/PTC 
rearrangements lead to a constitutively expressed and 
activated form of the RET proto-oncogene that is able to 
trigger transformation in PTC. The frequency of RET/PTC 
in PDTC has been reported to be considerably lower than in 
PTC (13-17%) [22, 57] or absent [9, 58]. Moreover, 
RET/PTC-positive PDTC are not associated with increased 
aggressiveness or poor patient survival and usually show 
histological evidence indicating coexistence with or possible 
evolution from a PTC often diagnosed as a classic, solid or 
tall cell variant PTC [7, 22, 57]. Concerning UTC, all 
previous studies reported an absence of RET/PTC 
rearrangements in this setting [22, 58]; only the study by 
Mochizuki et al. [59], who studied seven composite UTC 
(UTC having a PTC component) and 14 single component 
UTC, has found the presence of a RET/PTC3 rearrangement 
in both components (UTC and PTC) of one composite UTC, 
whereas all 14 single component UTC were RET/PTC-
negative.  
 The aforementioned works suggest that RET/PTC 
rearrangements do not seem to play a role in the progression 
of WDTC to PDTC. This appears also to be case for 
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PAX8/PPARg rearrangements, that were originally 
discovered in FTC and, later on, in follicular adenomas and 
follicular variant of PTC [60-63]; PAX8/PPARg 
rearrangements are absent from all PDTC and UTC so far 
analysed [9, 22]. 
WNT PATHWAY 
 -catenin mutations were reported in 25% and 65% of 
PDTC and UTC, respectively [55, 64-65]. The activating 
mutations cluster in exon-3, at the phosphorylation sites for 
ubiquitination and degradation of -catenin, and are 
associated with aberrant nuclear immunoreactivity, which is 
consistent with Wnt pathway activation [64-65]. According 
to these studies, -catenin mutations are restricted to PDTC 
and UTC, being significantly associated with poor prognosis 
and tumour differentiation, but not with conventional 
prognostic indicators for thyroid cancer. The results from 
Kim et al. [66], showing that transient overexpression of 
Wnt-1 or -catenin in FRTL-5 cells decreased 
thyroperoxidase (TPO) mRNA, and suppressed TPO-
promoter activity, corroborate a putative role for -catenin 
activation in loss of differentiation of thyroid cancer cells.  
 In contrast to the aforementioned results, Rocha et al. 
[67] did not find mutations in -catenin or E-cadherin genes 
in a series of PDTC; however, there was altered expression 
of E-cadherin/-catenin at the protein level, suggesting that 
loss of E-cadherin rather than -catenin mutations is the 
crucial event in determining the differentiation 'level' of 
thyroid carcinomas [67]. The quite different percentages of 
-catenin mutations reported in different series of PDTC [64-
65, 67-68] probably reflect the heterogeneity of tumours that 
are often included under the umbrella category of PDTC [8]. 
In other series of UTC, nuclear and cytoplasmic positivity 
for -catenin was found in 40% of the cases but mutations 
were only detected in 4.5% of the cases [68]. The same 
authors reported mutations in adenomatous polyposis coli 
(APC) and Axin 1 in 9.0%, and 81.8% of the ATC samples, 
respectively [68].  
TELOMERASE: LIMITLESS OF PROLIFERATIVE 
POTENTIAL? 
 Telomerase activation is known to be a hallmark of 
cancer [69], being detected in 80 to 90% of malignant 
tumours [70-71]. Some tumours may maintain their 
telomeres by an alternative mechanism, telomerase-
independent, designated as ALT (alternative lengthening of 
telomeres), which appears to maintain telomeres through 
recombination based interchromosomal exchange of 
sequence information [72-73]. 
 Thyroid tissue is a conditional-renewal tissue, which 
proliferates very slowly and rarely; human thyroid cells are 
supposed to divide about five times in the adult life [74]. In 
the thyroid gland there is not a well-defined stem cell 
population that might constitute a pool of cells responsible 
for retaining the capacity of division. Some authors, 
including us, have proposed that the so-called Solid Cell 
Nests (SCNs) of the thyroid, which are the embryonic 
remnants of the ultimobranchial body, may represent the 
pool of thyroid stem cells as they express several stem cell 
markers, namely telomerase [75]. Despite this, normal 
thyroid tissue is thought to be telomerase negative thus 
raising the possibility that reactivation of telomerase may be 
a useful marker for tumour development and, if there are 
quantitative differences between benign and malignant 
lesions, for making the differential diagnosis in difficult 
cases [76].  
 Several studies have examined telomerase activity in 
thyroid lesions and surrounding normal tissues using 
polymerase chain reaction (PCR) based TRAP (Telomeric 
Repeat Amplification Protocol) assay for detection of 
telomerase activity and RT-PCR or quantitative real time 
RT-PCR for detection of hTERT mRNA (Table 1). The 
results obtained in all the studies using TRAP to determine 
telomerase activity lead to a persistent source of uncertainty. 
 Thyroid carcinomas apparently display less frequent 
telomerase activation than other human carcinomas, being 
present in about 66% of all the thyroid carcinomas analysed 
to date (Table 1). Telomerase activation seems to be more 
frequent in UTC being detected in about 78% of the cases 
analysed (Table 1); this finding suggests that telomerase may 
contribute (or be associated) to more aggressive behaviour of 
thyroid cancer [77-79].  
 Telomerase activation was measured by expression of 
hTERT gene by RT-PCR in four studies. These studies 
showed a significant association between hTERT expression 
and telomerase activity. hTERT expression was not detected 
in normal adjacent thyroid tissue, but it was found in a high 
percentage of the carcinomas namely in UTC [77-78, 80-81] 
(Table 1). Putting together the results obtained in the 
measurement of telomerase activity by several authors 
(Table 1), the presence of telomerase is reported in 48% of 
PTC and in 71% of FTC (Table 1). 
 Summing up, telomerase activation is less frequent in 
thyroid carcinomas (about 66%) than in other types of 
human cancer (80 to 90%). The available evidence suggest 
that telomerase activity is up-regulated in thyroid neoplastic 
cells and may be a marker of aggressiveness in thyroid 
tumours, since it has been associated with malignancy, 
invasiveness, advanced thyroid carcinomas and with the 
progression of WDTC to UTC [77-79, 82-84]. As far as we 
are aware there are no studies reporting telomerase activation 
in PDTC. 
OTHER GENETIC ALTERATIONS 
 Due to the aggressive nature of most PDTC and every 
UTC, efforts have been put on the identification of other 
genetic alterations in less differentiated and undifferentiated 
thyroid carcinomas that could identify new therapeutic 
targets. This is the case for tyrosine kinase receptors that lie 
upstream of the two pathways – MAPK and PI3K/Akt – 
most commonly activated in UTC. Liu et al. [85] searched 
for alterations (mutations and copy gains) in several tyrosine 
kinase receptors (EGFR, PDGFR, PDGRF, VEGFR1, 
VEGRF2, KIT and MET) in a series of UTC and FTC. No 
mutations were observed in any of these receptors, but the 
frequency of copy number gain was high, particularly among 
UTC; overall, it was detected at least one copy number gain 
in 80% of UTC. Putting together the results on copy number 
gains and commonly found mutations (BRAF, RAS, 
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PIK3CA), 90% of UTC harboured at least one genetic 
alteration [85]. Considering the studies reported to date, it is 
evident that most of the genetic alterations in PDTC and 
UTC lead to activation of MAPK and PI3K/Akt pathways. 
This is strengthened by the recent finding of ALK 
(anaplastic lymphoma kinase) oncogenic mutations in 11% 
UTC cases; these mutations promote cell focus formation, 
anchorage-independent growth, and cell invasion and also 
increase the ability of ALK to activate the PI3K/Akt and 
MAP kinase pathways in established mouse cells [86]. It was 
proposed that the presence of ALK mutations in UTC may 
provide a basis for analyzing the clinical role of ALK 
inhibitors in this setting [86].  
 We have recently described that UTCs present frameshift 
mutation and genomic loss of LRP1B gene [87]. LRP1B 
localizes at 2q21, a susceptibility locus for familial non-
medullary thyroid cancer and encodes for a member of the 
endocytic low-density lipoprotein receptor superfamily. We 
have found that LRP1B frequently displays genomic loss 
both in cell lines and also in sporadic thyroid tumours, 
including 60% of UTCs. UTCs also show frequent 
methylation of the promoter region and, accordingly, the 
expression of LRP1B was lost in more than 80% of UTCs 
[87].  
 There is increasing evidence showing that altered 
expression of microRNAs plays an important role in cancer 
development. In this regard, Visone et al. [88] analysed the 
microRNA (miR) profile of UTC in comparison to the 
normal thyroid, having found that UTC displays an aberrant 
miR expression profile that clearly differentiates it from 
normal thyroid tissues. Overall, UTC showed 
downregulation of the majority of miR, four of them (miR-
30d, miR-125b, miR-26a and miR-30a-5p) being 
downregulated to a 3-fold level, suggesting that the 
downregulated miRs in UTC can function as tumour 
suppressor or differentiation genes [88]; these results were 
further confirmed by Schwertheim et al. [89], who found 
that the same four miRs were significantly upregulated in 
PTC and downregulated in UTC, whereas in PDTC only 3/5 
were downregulated. In another study, Braun et al. [90] also 
showed that UTC presented a general downregulation of 
miRs comparing to normal thyroid and also to PTC and 
FTC. The authors identified two significantly decreased 
microRNA families (miR-200 and miR-30) that 
Table 1. Summary of Published Studies on Telomerase Activity in Thyroid Neoplasias 
Authors Normal adjacent 
thyroid tissue** 
Follicular 
adenoma** 
Follicular 
carcinoma** 
Papillary 
carcinoma** 
Anaplastic 
carcinoma** 
Saji et al.  [92]  0/10 0/3 _ 20/30 _ 
Saji et al.  [80]* 0/12* 2/7* 6/6* 9/13* _ 
Aogi et al. [81] _ 0/11 3/3 5/5 1/2 
(same cases) _ 5/11* 3/3* 2/5* 2/2* 
Aogi et al. [93] _ 0/9 3/3 5/5 1/2 
Yashima et al. [94]  3/22 1/5 0/2 4/11 _ 
Umbricht et al. [83]  0/22 5/23 11/11 _ _ 
Cheng et al. [95] _ 4/14 10/11 12/23 _ 
Brousset et al. [79] 0/20 1/12 4/6 3/15 2/3 
De Deken et al. [96] 3/28 1/28 _ _ _ 
Okayasu et al. [84] 0/26 9/23 3/4 16/26 _ 
Haugen et al. [97]  3/14 0/14 0/3 10/14 0/1 
Lo et al. [98] 0/35 0/9 0/2 15/52 1/2 
Onoda et al. [99] 5/14 0/2 _ 9/16 1/1 
Kammori et al. [100] 1/21 3/9 3/3 7/8 _ 
Sebesta et al. [101] _ 3/4 _ 2/3 _ 
Matthews et al. [102] 0/10 3/22 6/16 8/37 _ 
Takano T et al. [78] _ _ _ _ 12/12*+ 
Total 15/234 
(6.4%) 
37/212  
(17.5%) 
52/73 
(71.2%) 
127/263 
(48.3%) 
18/23 
(78.3%) 
*Telomerase subunit hTERT was analysed by RT-PCR *+ Telomerase subunit hTERT was analysed by real-time quantitative RT-PCR; all the other studies were performed only by 
TRAP. 
**Positive cases/total cases (percentage positive in parentheses).  
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unambiguously distinguish UTCs from PTC and FTC. 
Expression of these microRNAs in mesenchymal UTC-
derived cells reduced their invasive potential and induced 
mesenchymal–epithelial transition, suggesting that the 
altered microRNA signatures in UTC may play a role in the 
promotion of de-/transdifferentiation (epithelial-
mesenchymal transition) and invasion of these neoplasias 
[90].  
 Other genes and pathways important for the development 
of PDTC and UTC may include, for example, those 
involving metabolic remodelling; in fact, after the recent 
identification of isocitrate dehydrogenase mutations in 
glioblastomas (that share the aggressive behaviour with 
PDTC and UTC), other types of cancer have also been 
screened for IDH mutations. In thyroid cancer, IDH 
mutations were detected in 11% of the UTC cases [91]; 
although IDH mutations do not seem to be particularly 
prevalent in UTC, they are functionally relevant and may put 
forward a new therapeutic approach for such a lethal cancer 
as UTC [91].  
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